Immunogenicity Induced by COVID-19 Vaccines in Mexican Population (Vaccines COVID)

National Polytechnic Institute, Mexico

Status: Completed

Conditions: COVID-19 Vaccine

Treatments: Other: Gene expression mRNA of IgG anti-spike

Study type: Observational

Funder types: Other

Identifiers

NCT06597370

CEI-01-2021

Details and patient eligibility

About

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Full description

80 subjects with full vaccination schedule will be included, 20 per group To know the gene expression of IgG anti-spike through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. • Mexican people.
2. • Over 18 years of age.
3. • With complete vaccination schedule against COVID-19.
4. • Allowing peripheral blood samples to be taken.
5. • To sign an informed consent form.
6. • To agree to participate in the protocol.

Exclusion criteria

1. • Persons with incomplete vaccination schedule against COVID-19.
2. • Persons who have 30 +/- 5 days of having completed the vaccination scheme against COVID-19.
3. • People under treatment with any immunosuppressive drug.
4. People who refuse to sign the informed consent form.

Trial design

80 participants in 4 patient groups

Group 1

Description:

20 persons who have received the Oxford/AstraZeneca vaccine (ChAdOx1 nCoV-19).

Treatment:

Other: Gene expression mRNA of IgG anti-spike

Group 2

Description:

20 persons who have received the vaccine Gamaleya National Center(Sputnik V)

Treatment:

Other: Gene expression mRNA of IgG anti-spike

Group 3

Description:

20 persons who have received the Pfizer/BioNTech vaccine (BNT162b2).

Treatment:

Other: Gene expression mRNA of IgG anti-spike

Group 4

Description:

20 persons who have received the Sinovac (CoronaVac) vaccine.

Treatment:

Other: Gene expression mRNA of IgG anti-spike